PM8002 in the Treatment of Patients With Advanced Solid Tumors

December 3, 2024 updated by: Biotheus Inc.

Phase Ib/IIa Safety and Efficacy of PM8002, a Bispecific Antibody Targeting PD-L1 and VEGF-A, as a Monotherapy in Patients With Advanced Solid Tumors

This study is to characterize the safety, tolerability, pharmacokinetics (PK), immunogenicity, pharmacodynamics (PD) and anti-tumor activity of PM8002, a PD-L1/VEGF bispecific antibody, as a single agent in adult subjects with advanced solid tumors.

Study Overview

Status

Status

Indicates the current recruitment status or the expanded access status.
Recruiting

Conditions

Conditions

The disease, disorder, syndrome, illness, or injury that is being studied. On ClinicalTrials.gov, conditions may also include other health-related issues, such as lifespan, quality of life, and health risks.

Intervention / Treatment

Intervention / Treatment

A process or action that is the focus of a clinical study. Interventions include drugs, medical devices, procedures, vaccines, and other products that are either investigational or already available. Interventions can also include noninvasive approaches, such as education or modifying diet and exercise.

Study Type

Study Type

Describes the nature of a clinical study. Study types include interventional studies (also called clinical trials), observational studies (including patient registries), and expanded access.
Interventional

Enrollment (Estimated)

Enrollment

The number of participants in a clinical study. The "anticipated" enrollment is the target number of participants that the researchers need for the study.
380

Phase

Phase

The stage of a clinical trial studying a drug or biological product, based on definitions developed by the U.S. Food and Drug Administration (FDA). The phase is based on the study's objective, the number of participants, and other characteristics. There are five phases: Early Phase 1 (formerly listed as Phase 0), Phase 1, Phase 2, Phase 3, and Phase 4. Not Applicable is used to describe trials without FDA-defined phases, including trials of devices or behavioral interventions.
  • Phase 2
  • Phase 1

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Contact

Study Contact

The name and contact information for the person who can answer enrollment questions for a clinical study. Each location where the study is being conducted may also have a specific contact, who may be better able to answer those questions.

Study Locations

  • China
      • Baoji, China
        • Recruiting
        • Baoji Central Hospital
        • Principal Investigator:
          • Gang Wang
        • Contact:
          • Gang Wang
      • Beijing, China
        • Recruiting
        • Peking University Cancer Hospital
        • Principal Investigator:
          • Lin Shen
        • Contact:
          • Lin Shen
      • Beijing, China
        • Recruiting
        • Cancer Hospital Chinese Academy of Medical Sciences
        • Contact:
          • Lingying WU
        • Principal Investigator:
          • Lingying Wu
      • Changchun, China
        • Recruiting
        • Jilin Cancer Hospital
        • Principal Investigator:
          • Ying Cheng
        • Contact:
          • Yng Cheng
      • Changchun, China
        • Recruiting
        • The First Hospital of Jilin University
        • Contact:
          • Jiuwei Cui
        • Principal Investigator:
          • Jiuwei Cui
      • Changde, China
        • Recruiting
        • Changde First People's Hospital
        • Contact:
          • Tao Wu
        • Principal Investigator:
          • Tao Wu
      • Changsha, China
        • Recruiting
        • Hunan Provincial People's Hospital
        • Contact:
          • Huaxin Duan
        • Principal Investigator:
          • Huaxin Duan
      • Changzhou, China
        • Recruiting
        • The First People's Hospital of Changzhou
        • Principal Investigator:
          • Mei Ji
        • Contact:
          • Mei Ji
      • Chengdu, China
        • Recruiting
        • Sichuan Cancer Hospital
        • Contact:
          • Yongdong Jin
        • Principal Investigator:
          • Yongdong Jin
      • Chengdu, China
        • Recruiting
        • Chengdu Integrated TCM& Western Medicine Hospital
        • Contact:
          • Ping Li
        • Principal Investigator:
          • Ping Li
      • Chongqing, China
        • Recruiting
        • Chongqing Cancer Hospital
        • Principal Investigator:
          • Hong Luo
        • Contact:
          • Hong Luo
      • Chongqing, China
        • Recruiting
        • The First Affiliated Hospital of Chongqing Medical University
        • Contact:
          • Chengyou Du
        • Principal Investigator:
          • Chengyou Du
      • Chongqing, China
        • Recruiting
        • The Southwest Hospital of Amu
        • Contact:
          • Zhiqing Liang
        • Principal Investigator:
          • Zhiqing Liang
      • Fuzhou, China
        • Recruiting
        • Fujian Cancer Hospital
        • Principal Investigator:
          • Yu Chen
        • Contact:
          • Yu Chen
      • Hangzhou, China
        • Recruiting
        • Zhejiang Provincial People's Hospital
        • Contact:
          • Zhiquan Qin
        • Principal Investigator:
          • Zhiquan Qin
      • Harbin, China
        • Recruiting
        • Harbin medical university cancer hospital
        • Contact:
          • Baogang Liu
        • Principal Investigator:
          • Baogang Liu
      • Hefei, China
        • Recruiting
        • Anhui Provincial Hospital
        • Principal Investigator:
          • Yueyin Pan
        • Contact:
          • Yueyin Pan
      • Linyi, China
        • Recruiting
        • Linyi Cancer Hospital
        • Principal Investigator:
          • Zhen Wang
        • Contact:
          • Jingfen Wang
      • Nanjing, China
        • Recruiting
        • Jiangsu Province Hospital
        • Principal Investigator:
          • Zengjun Wang
        • Contact:
          • Zengjun Wang
      • Shanghai, China
        • Recruiting
        • Shanghai Sixth People's Hospital
        • Contact:
          • Hun Zhao
        • Principal Investigator:
          • Hun Zhao
      • Shanghai, China
        • Recruiting
        • Shanghai Orient Hospital
        • Contact:
        • Principal Investigator:
          • Ye Guo
      • Shengjing, China
        • Recruiting
        • Shengjing Hospital Of China Medical University
        • Principal Investigator:
          • Bin Wu
        • Contact:
          • Bin Wu
      • Shenyang, China
        • Recruiting
        • Liaoning Cancer Hospital
        • Contact:
          • Chunyan Wang
        • Principal Investigator:
          • Chunyan Wang
      • Shenyang, China
        • Recruiting
        • The First Hospital of China Medical University
        • Contact:
          • Funan Liu
        • Principal Investigator:
          • Funan Liu
      • Shenyang, China
        • Recruiting
        • The People's Hospital of Liaoning Province
        • Contact:
          • Lijie He
        • Principal Investigator:
          • Lijie He
      • Shijiazhuang, China
        • Recruiting
        • The Fourth Hospital of Hebei Medical University
        • Principal Investigator:
          • Da Jiang
        • Contact:
          • Da Jiang
      • Taiyuan, China
        • Recruiting
        • Shanxi Bethune Hospital
        • Contact:
          • Huijing Feng
        • Principal Investigator:
          • Huijing Feng
      • Taiyuan, China
        • Recruiting
        • Shanxi Provincial Cancer hospital
        • Principal Investigator:
          • Shuqing Wei
        • Contact:
          • Shuqing Wei
      • Taizhou, China
        • Recruiting
        • Taizhou Hospital of Zhejiang Province
        • Contact:
          • Dongqing Lv
        • Principal Investigator:
          • Dongqing LV
      • Tianjin, China
        • Recruiting
        • The Second Hospital Of Tianjin Medical University
        • Contact:
          • Gang Li
        • Principal Investigator:
          • Gang Li
      • Wuhan, China
        • Recruiting
        • Union Hospital Tongji Medical College Huazhong University of Science and Technology
        • Contact:
          • Guiling Li
        • Principal Investigator:
          • Guiling Li
      • Wuhan, China
        • Recruiting
        • Hubei Cancer Hospital
        • Principal Investigator:
          • Yi Huang
        • Contact:
          • Yi Huang
      • Xi'an, China
        • Recruiting
        • The First Affiliated Hospital of Xi'an Jiaotong University
        • Contact:
          • Ruifang An
        • Principal Investigator:
          • Ruifang An
      • Xi'an, China
        • Recruiting
        • Xi 'an International Medical Center Hospital
        • Contact:
          • Kejun Nan
        • Principal Investigator:
          • Kejun Nan
      • Yantai, China
        • Recruiting
        • Yantai Yuhuangding Hospital
        • Principal Investigator:
          • Jitao Wu
        • Contact:
          • Jitao Wu
      • Yibin, China
        • Recruiting
        • Yibin Second People's Hospital
        • Contact:
          • Kaijian Lei
        • Principal Investigator:
          • Kaijian Lei
      • Zhengzhou, China
        • Recruiting
        • Henan Cancer Hospital
        • Principal Investigator:
          • Suxia Luo
        • Contact:
          • Suxia Luo
      • Zhengzhou, China
        • Recruiting
        • The first affilated hospital of zhengzhou university
        • Contact:
          • Xingya Li
        • Principal Investigator:
          • Xingya Li
      • Zhujiang, China
        • Recruiting
        • Zhujiang Hospital of Southern Medical University
        • Principal Investigator:
          • Jian Zhang
        • Contact:
          • Jian Zhang

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Eligibility Criteria

The key requirements that people who want to participate in a clinical study must meet or the characteristics they must have. Eligibility criteria consist of both inclusion criteria (which are required for a person to participate in the study) and exclusion criteria (which prevent a person from participating). Types of eligibility criteria include whether a study accepts healthy volunteers, has age or age group requirements, or is limited by sex.

Ages Eligible for Study

  • Adult
  • Older Adult

Accepts Healthy Volunteers

No

Description

Inclusion Criteria:

  1. Voluntary participation in clinical study; fully understand the study and sign informed consent voluntarily; willing to follow and able to complete all test procedures;
  2. Male or female aged 18 to 75 years;
  3. Patients with malignant tumor confirmed by histology or cytology;
  4. The toxicity of previous anti-tumor therapy has not been alleviated；
  5. Adequate organ function；
  6. ECOG score was 0-1;
  7. Expected survival >=12 weeks;
  8. According to RECIST 1.1 criteria, at least 1 measurable lesion that has not been previously treated locally.

Exclusion Criteria:

  1. History of severe allergic disease, severe allergy to drugs or known allergy to any component of the drug in this study;
  2. Evidence of major coagulopathy or other obvious risk of bleeding;
  3. Patients are experiencing a clear interstitial lung disease or non-infectious pneumonia, unless it is caused by local radiotherapy;
  4. Patients with uncontrolled brain metastases should be excluded from this clinical trial;
  5. Patients ever experienced other active malignant tumors within 5 years prior to the study treatment;
  6. Prior allogeneic organ transplantation or allogeneic hematopoietic stem cell transplantation;
  7. Known history of alcohol abuse, psychotropic drug abuse or drug abuse;
  8. Syphilis antibody positive;
  9. Patients with active tuberculosis (TB) are excluded;
  10. Pregnant or lactating women;
  11. Other conditions lead to inappropriate to participate in this study as judged by the investigator.

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Treatment
  • Allocation: N/A
  • Interventional Model: Sequential Assignment
  • Masking: None (Open Label)

Arms and Interventions

Participant Group / Arm

Participant Group / Arm

A group or subgroup of participants in a clinical trial that receives a specific intervention/treatment, or no intervention, according to the trial's protocol.
Intervention / Treatment

Intervention / Treatment

A process or action that is the focus of a clinical study. Interventions include drugs, medical devices, procedures, vaccines, and other products that are either investigational or already available. Interventions can also include noninvasive approaches, such as education or modifying diet and exercise.
Experimental: PM8002
PM8002 IV every 2 weeks(q2w) or every 3 weeks(q3w)
Drug: PM8002
IV infusion

What is the study measuring?

Primary Outcome Measures

Primary Outcome Measures

In a clinical study's protocol, the planned outcome measure that is the most important for evaluating the effect of an intervention/treatment. Most clinical studies have one primary outcome measure, but some have more than one.
Outcome Measure
Measure Description
Time Frame
Treatment related adverse events (TRAEs)
Time Frame: Up to 30 days after last treatment
The incidence and severity of TRAEs graded according to NCI-CTCAE v5.0
Up to 30 days after last treatment
Number of participants with DLTs
Time Frame: During the first three weeks of treatment with PM8002
DLTs will be assessed during the dose-escalation phase and are defined as toxicities that meet pre-defined severity criteria and assessed as having a suspected relationship to study drug, and unrelated to disease, disease progression, intercurrent illness, or concomitant medications that occurs within the first cycle (3weeks) of treatment.
During the first three weeks of treatment with PM8002
Objective response rate (ORR)
Time Frame: Up to approximately 2 years
Objective response rate (ORR) is the proportion of subjects with complete response (CR) or partial response (PR), based on RECIST v1.1.
Up to approximately 2 years

Secondary Outcome Measures

Secondary Outcome Measures

In a clinical study's protocol, a planned outcome measure that is not as important as the primary outcome measure for evaluating the effect of an intervention but is still of interest. Most clinical studies have more than one secondary outcome measure.
Outcome Measure
Measure Description
Time Frame
Disease control rate (DCR)
Time Frame: Up to approximately 2 years
DCR is defined as the proportion of subjects with CR, PR, or stable disease(SD) based on RECIST v1.1.
Up to approximately 2 years
Anti-drug antibody (ADA)
Time Frame: Up to 30 days after last treatment
To evaluate the incidence of ADA to PM8002.
Up to 30 days after last treatment
Overall survival (OS)
Time Frame: Up to approximately 2 years
OS is the time from the date of first dosing date to death due to any cause.
Up to approximately 2 years
Duration of response (DoR)
Time Frame: Up to approximately 2 years
DoR is defined as the duration from the first documentation of objective response to the first documented disease progression (based on RECIST v1.1). for subjects with no documented disease progression, the deadline is the data of the last examination.
Up to approximately 2 years
Progression-free survival (PFS)
Time Frame: Up to approximately 2 years
Progression-free survival is defined as the time from the start of treatment with PM8002 until the first documentation of disease progression or death due to any cause, whichever occurs first.
Up to approximately 2 years

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

Sponsor

The organization or person who initiates the study and who has authority and control over the study.
Biotheus Inc.

Investigators

Investigators

A researcher involved in a clinical study. Related terms include site principal investigator, site sub-investigator, study chair, study director, and study principal investigator.
  • Principal Investigator: Ye Guo, Shanghai Orient Hospital

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

Study Start

The actual date on which the first participant was enrolled in a clinical study. The "anticipated" study start date is the date that the researchers think will be the study start date.
March 9, 2021

Primary Completion (Estimated)

Primary Completion

The date on which the last participant in a clinical study was examined or received an intervention to collect final data for the primary outcome measure. Whether the clinical study ended according to the protocol or was terminated does not affect this date. For clinical studies with more than one primary outcome measure with different completion dates, this term refers to the date on which data collection is completed for all the primary outcome measures. The "anticipated" primary completion date is the date that the researchers think will be the primary completion date for the study.
November 30, 2025

Study Completion (Estimated)

Study Completion

The date on which the last participant in a clinical study was examined or received an intervention/treatment to collect final data for the primary outcome measures, secondary outcome measures, and adverse events (that is, the last participant's last visit). The "anticipated" study completion date is the date that the researchers think will be the study completion date.
November 30, 2025

Study Registration Dates

First Submitted

First Submitted

The date on which the study sponsor or investigator first submitted a study record to ClinicalTrials.gov. There is typically a delay of a few days between the first submitted date and the record's availability on ClinicalTrials.gov (the first posted date).
May 30, 2023

First Submitted That Met QC Criteria

First Submitted That Met QC Criteria

The date on which the study sponsor or investigator first submits a study record that is consistent with National Library of Medicine (NLM) quality control (QC) review criteria. The sponsor or investigator may need to revise and submit a study record one or more times before NLM's QC review criteria are met. It is the responsibility of the sponsor or investigator to ensure that the study record is consistent with the NLM QC review criteria.
June 15, 2023

First Posted (Actual)

First Posted

The date on which the study record was first available on ClinicalTrials.gov after National Library of Medicine (NLM) quality control (QC) review has concluded. There is typically a delay of a few days between the date the study sponsor or investigator submitted the study record and the first posted date.
June 26, 2023

Study Record Updates

Last Update Posted (Estimated)

Last Update Posted

The most recent date on which changes to a study record were made available on ClinicalTrials.gov. There may be a delay between when the changes were submitted to ClinicalTrials.gov by the study's sponsor or investigator (the last update submitted date) and the last update posted date.
December 5, 2024

Last Update Submitted That Met QC Criteria

Last Update Submitted That Met QC Criteria

The most recent date on which the study sponsor or investigator submitted changes to a study record that are consistent with National Library of Medicine (NLM) quality control (QC) review criteria. It is the responsibility of the sponsor or investigator to ensure that the study record is consistent with the NLM QC review criteria.
December 3, 2024

Last Verified

Last Verified

The most recent date on which the study sponsor or investigator confirmed the information about a clinical study on ClinicalTrials.gov as accurate and current. If a study with a recruitment status of recruiting; not yet recruiting; or active, not recruiting has not been confirmed within the past 2 years, the study's recruitment status is shown as unknown.
November 1, 2024

More Information

Terms related to this study

Additional Relevant MeSH Terms

Other Study ID Numbers

Other Study ID Numbers

Identifiers or ID numbers other than the NCT number that are assigned to a clinical study by the study's sponsor, funders, or others. These numbers may include unique identifiers from other trial registries and National Institutes of Health grant numbers.
  • PM8002-A001

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

YES

IPD Plan Description

The data will be published or presented for publications (poster, abstract, articles or papers) or any presentations.

IPD Sharing Time Frame

After the trial completed

IPD Sharing Access Criteria

NCI is committed to sharing data in accordance with NIH policy.

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Malignant Neoplasm

Clinical Trials on PM8002

Search Similar Trials

Sponsors and Collaborators

Medical Conditions

Drug Interventions

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations

Cookie Settings

We use cookies to ensure that we give you the best experience on our website. For more details carefully read our Privacy and Cookies Policy. ...>>>You can change your preferences or withdraw your consent at any time by deleting the cookies from your website or computer as described in the policy. Please accept it and choose your preferences by ticking the corresponding boxes in the "Manage Settings" section below. Please carefully read our Terms of Service before you proceed with using any part of this website.
«Manage Settings